Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47633
Title: | Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey | Authors: | Ozturk S. Gursu M. Arici M. Sahin I. Eren N. Yilmaz M. Koyuncu S. Karahisar Sirali, Semahat Ural, Zeynep Dursun, Belda Yuksel, Enver Uzun, Sami Sipahi, Savas Ahbap, Elbis Yazici, Halil Altunoren, Orcun Tunca, Onur Ayar, Yavuz Gok Oguz, Ebru Kahvecioglu, Serdar Asicioglu, Ebru Oruc, Aysegul Ataman, Rezzan Aydin, Zeki Huddam, Bulent Dolarslan, Murside Esra Azak, Alper Bakirdogen, Serkan Yalcin, Ahmet Ugur Karadag, Serhat Ulu, Memnune Sena Gungor, Ozkan Ari Bakir, Elif Odabas, Ali Riza Seyahi, Nurhan Yildiz, Alaattin Ates, Kenan |
Keywords: | Complication COVID-19 Outcome Peritoneal dialysis |
Publisher: | S. Karger AG | Abstract: | Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia. © 2022 S. Karger AG, Basel. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. | URI: | https://doi.org/10.1159/000526234 https://hdl.handle.net/11499/47633 |
ISSN: | 1660-8151 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Evaluation of Outcomes.pdf | 269.57 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
3
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
2
checked on Nov 22, 2024
Page view(s)
64
checked on Aug 24, 2024
Download(s)
16
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.